Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of ...

Investing.com -- Shares of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) surged 18% after the company announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would ...

Reports Q4 revenue $2.6M, consensus $3.35M.”With commercial preparations underway, we believe we are well positioned to launch TNX-102 SL for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research ...

TNX-102 SL was generally well tolerated and has no known addictive properties. Dr. Lederman continued, “Tonix is debt free and expects to have sufficient cash to fund operations through the ...

Ms. Fogarty originally joined Tonix in 2016 and has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality, for both small and large molecules ...